The health secretary has chipped away at the idea that immunizing children against measles and other diseases is a public ...

The former top vaccines official at the Food and Drug Administration criticized Health and Human Services Secretary Robert F.

Directives from President Donald Trump's administration to freeze grant funding from the National Institutes of Health may ...

(Reuters) -Vaccine maker Novavax's shares plunged nearly 20% at market close on Thursday, after Health and Human Services ...

As in previous studies, the SHIELD study found health care workers who received the Novavax vaccine reported significantly ...

Shares of Novavax Inc. NVAX shed 3.23% to $6.00 Thursday, on what proved to be an all-around dismal trading session for the ...

Novavax (NasdaqGS:NVAX) recently announced promising preliminary results from the SHIELD-Utah study, which highlighted fewer and less severe reactogenicity symptoms for its COVID-19 Vaccine, ...

Novavax (NVAX) closed the most recent trading day at $6.39, moving -0.31% from the previous trading session. This move lagged the S&P 500's daily loss of 0.17%. Meanwhile, the Dow experienced a drop ...

According to TipRanks, Stranahan is an analyst with an average return of -15.0% and a 32.39% success rate. Stranahan covers the Healthcare sector, focusing on stocks such as Candel Therapeutics, ...

As the prospect of sector-specific tariffs under the second Trump administration continues to rattle drugmakers, a more ...

Workers who received Novavax reported 12.5% fewer local reactions than those who received the Pfizer vaccine. Average hours ...